New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
07:06 EDTINSYInsys Therapeutics submits Type II DMF to FDA for CBD API
Insys Therapeutics announced it has submitted a Type II Drug Master File, or DMF, to the FDA for its cannabidiol, or CBD, active pharmaceutical ingredient, or API, and has been issued DMF# 28255. Insys recently announced plans to advance development of its pharmaceutical CBD program for the treatment of epilepsy in children and adults.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
08:11 EDTINSYInsys Therapeutics receives FDA ODD for LEP candidate
Insys Therapeutics announced that the FDA has granted orphan drug designation, or ODD, to its Liposomal Encapsulated Paclitaxel, or LEP, candidate for the treatment of ovarian cancer.
January 22, 2015
11:05 EDTINSYInsys Therapeutics granted orphan status for ovarian cancer treatment
Subscribe for More Information
January 12, 2015
07:02 EDTINSYInsys Therapeutics to initiate five Phase III trials in FY15
Insys Therapeutics announced progress and expected milestones for multiple projects in its pipeline of innovative supportive care and therapy products and candidates. The company intends to submit a New Drug Application to the FDA and to advance five programs into Phase III clinical trials in 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use